Efficacy and Safety of Aflibercept 8 mg in PULSAR Trial in Neovascular AMD

Opinion
Video

Dr. Marion Munk reviews the Phase 3 clinical trial of high-dose aflibercept (8 mg) in neovascular AMD, emphasizing how this new therapy could alleviate the treatment burden for patients while providing superior outcomes.

Related Videos
Marion Munk, MD, PhD, presenting slides
Related Content
Outlook Therapeutics submits UK Marketing Authorization Application for wet AMD treatment

Outlook Therapeutics submits UK Marketing Authorization Application for wet AMD treatment

May 15th 2024
Article
I-SCREEN project set to use AI for AMD diagnosis across Europe

I-SCREEN project set to use AI for AMD diagnosis across Europe

April 17th 2024
Article
India-based Eyestem receives approval to commence human trial for Eyecyte RPE for AMD

India-based Eyestem receives approval to commence human trial for Eyecyte RPE for AMD

April 14th 2024
Article
EyePoint shared additions to scientific advisory board and conditional approval of trade name for EYP-1901

EyePoint shared additions to scientific advisory board and conditional approval of trade name for EYP-1901

April 11th 2024
Article
John Han, PharmD named Vice President, Medical Affairs for Opthea Limited

John Han, PharmD named Vice President, Medical Affairs for Opthea Limited

April 10th 2024
Article
Clinical trials: Companies tackle AMD in early 2024

Clinical trials: Companies tackle AMD in early 2024

April 2nd 2024
Article
© 2024 MJH Life Sciences

All rights reserved.